Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
St. Jude Children's Research Hospital
Valent Technologies, LLC
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Second Life Therapeutics
Instituto do Cancer do Estado de São Paulo
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Siriraj Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
Universitätsklinikum Hamburg-Eppendorf
Bayer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
National Cancer Institute (NCI)
New York Medical College
Children's National Research Institute
City of Hope Medical Center
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Emory University
Children's Oncology Group
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Children's Oncology Group
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)